<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620865</url>
  </required_header>
  <id_info>
    <org_study_id>2015-100</org_study_id>
    <secondary_id>NCI-2015-01942</secondary_id>
    <secondary_id>1510014428</secondary_id>
    <secondary_id>2015-100</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT02620865</nct_id>
  </id_info>
  <brief_title>Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed
      activated T-cells when given together with aldesleukin and sargramostim and to see how well
      they work in treating patients with pancreatic cancer that has spread from where it started
      to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic).
      Bispecific antibody armed activated T-cells are the patient's own T cells that are coated
      with a bispecific antibody comprising 2 antibodies chemically joined together. These
      antibodies have specific targets and binding properties that may give the T cells a greater
      ability to seek out, attach to, and kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Confirm in a single dose phase I (3 to 6 patients [pts]) that 8 infusions of 10^10
      epidermal growth factor receptor (EGFR) bispecific antibody armed activated T cells (BATs)
      given twice per week in combination with interleukin (IL)-2 (aldesleukin) (300,000
      IU/m^2/day) and granulocyte-macrophage colony stimulating factor (GM-CSF) (sargramostim) (250
      ug/m^2/twice weekly) beginning 3 days before the 1st infusion and ending on the day of the
      last infusion is safe.

      II. Perform a phase II clinical trial to estimate the clinical efficacy of 8 infusions of
      10^10 EGFR BATs in combination with IL-2 and GM-CSF in 39 evaluable pts (including the 3-6
      pts in the single dose phase I).

      SECONDARY OBJECTIVES:

      I. Determine if infusions of EGFR BATs significantly increase cellular or humoral
      anti-pancreatic cancer (PC) responses by peripheral blood mononuclear cells (PBMC) at
      different time points after last EGFR BATs infusion and if those responses persist beyond 2
      months (mos).

      II. Obtain original tumor paraffin blocks prior to treatment and evaluate blocks for cluster
      of differentiation (CD)3, CD4, CD8, programmed cell death (PD)1/programmed cell death ligand
      (PDL)1, monocytes subpopulations, myeloid-derived suppressor cells (MDSC), and cytoplasmic
      interferon (IFN)-gamma and IL-10 by immunohistochemical staining to quantitate type and
      number of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment to estimate
      whether the type and number correlate with clinical responses.

      III. To determine the time to progression (TTP).

      OUTLINE: This is a phase Ib, dose-escalation study of anti-CD3 x anti-EGFR-bispecific
      antibody armed activated T-cells followed by a phase II study.

      Patients receive one of the following standard chemotherapy regimens at the discretion of the
      treating physician: gemcitabine hydrochloride intravenously (IV) over 30 minutes; gemcitabine
      hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation
      IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and
      leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV
      over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2
      weeks after standard chemotherapy completion, patients receive anti-CD3 x
      anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4
      weeks. Patients also receive aldesleukin subcutaneously (SC) and sargramostim SC on day -3
      before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion
      and continuing twice weekly until the final infusion.

      After completion of study treatment, patients are followed up for 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Descriptive statistics (point and exact 90% confidence interval estimates from the resultant Kaplan-Meier curve) will be generated for OS. The median OS will be estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed all BAT infusions) using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis (including CD3, CD4, CD8, PD1, PDL1, monocytes, MDSC, IFN-gamma, IL-10, and TILs) assessed using immunohistochemistry</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Each biomarker and computed biomarker will be evaluated for normality and transformed (including non-parametric) if necessary to achieve normality. Summary statistics (including means, medians, and standard deviations) will be produced for each variable and subsequently associate each variable with OS using Cox regression. In addition, a threshold for each variable associating with OS will be defined using classification and regression trees.
The tumor will be stained for inflammatory biomarkers. Specifically, T cells with undergo cytoplasmic staining for IFN and IL-10 and the level and ratio of these markers will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity CTCAE version 4.0</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Toxicity rates will be estimated using all treated patients. Point and 90% Wilson's confidence intervals will be estimated to describe binary endpoints including toxicity rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Descriptive statistics (point and exact 90% confidence interval estimates from the resultant Kaplan-Meier curve) will be generated for PFS. The median PFS will be estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed all BAT infusions) using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative immune response</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>For the quantitative immune response variables, summary statistics (including means, medians, and standard deviations) will be produced pre- and post-BATs treatment. Subsequent analyses will compare the immune response variables (after a suitable transformation, if necessary) pre- and post-treatment using a paired t-test (or Wilcoxon sign ranked test if the data are not approximately normally distributed). To explore whether immune responses associate with clinical responses, the association between the baseline of each biomarker and clinical endpoints (such as response, or OS) will be analyze</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>To explore whether immune responses associate with clinical responses, the association between the baseline of each biomarker and clinical endpoints (such as response, or OS) will be analyzed using logistic regression for binary endpoints and Cox regression for time to event endpoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Recurrent Pancreatic Carcinoma</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antibody Therapy</intervention_name>
    <description>Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>passive antibody therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Actino-Hermal</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Arumel</other_name>
    <other_name>Cytosafe</other_name>
    <other_name>Efudex</other_name>
    <other_name>Efurix</other_name>
    <other_name>Fiverocil</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Flurox</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
    <other_name>Timazin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Camptothecin 11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>CPT 11</other_name>
    <other_name>CPT-11</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Albumin-Stabilized Nanoparticle Formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>nab-paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>protein-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (anti-CD3 x anti-EGFR BATs)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proof of pancreatic adenocarcinoma; must have locally
             advanced or metastatic pancreatic cancer who have received at least first line
             chemotherapy and may have responding, stable or progressive disease

          -  Expected survival &gt;= 3 months

          -  Karnofsky performance scale (KPS) &gt;= 70% or Southwestern Oncology Group (SWOG)
             performance status 0 or 1

          -  Absolute neutrophil count (ANC) &gt;= 1,000/mm^3

          -  Lymphocyte count &gt;= 400/mm^3

          -  Platelet count &gt;= 75,000/mm^3

          -  Hemoglobin &gt;= 8 g/dL

          -  Serum creatinine &lt; 2.0 mg/dl, creatinine clearance &gt;= 50 ml/mm (can be calculated or
             measured)

          -  Total bilirubin =&lt; 2 mg/dl (biliary stent is allowed)

          -  Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic
             transaminase (SGOT) &lt; 5.0 times normal

          -  Left ventricular ejection fraction (LVEF) &gt;= 45% at rest (multigated acquisition scan
             [MUGA] or echocardiogram [Echo])

          -  Females of childbearing potential, and males, must be willing to use an effective
             method of contraception

          -  Females of childbearing potential must have a negative pregnancy test within 7 days of
             being registered for protocol therapy

        Exclusion Criteria:

          -  Any chemotherapy related toxicities from prior treatment (&gt; grade 2 per Common
             Terminology Criteria for Adverse Events [CTCAE] version [v]4.0)

          -  Known hypersensitivity to cetuximab or other EGFR antibody

          -  Treatment with any investigational agent within 14 days prior to being registered for
             protocol therapy

          -  Symptomatic brain metastasis

          -  Chronic treatment with systemic steroids or another immuno-suppressive agent

          -  Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy
             or significant traumatic injury within 28 days prior to being registered for protocol
             therapy

          -  Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
             hepatitis

          -  Known human immunodeficiency virus (HIV) infection

          -  Active bleeding or a pathological condition that is associated with a high risk of
             bleeding (therapeutic anticoagulation is allowed)

          -  Has an active infection requiring systemic therapy

          -  A serious uncontrolled medical disorder that in the opinion of the investigator may be
             jeopardized by the treatment with protocol therapy

          -  Females must not be breastfeeding

          -  Patient (Pt) may be excluded if, in the opinion of the principal investigator (PI) and
             investigator team, the pt is not capable of being compliant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Shields</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony Shields</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

